FRAT2 Polyclonal Antibody, FITC Conjugated
Product Specifications
Background
FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.
Synonyms
Frequently rearranged in advanced T-cell lymphomas 2 antibodyGSK-3 binding protein FRAT2; FRAT2_HUMAN.
Gene ID
23401
Cellular Locus
Cytoplasm
Host
Rabbit
Cross Reactivity
Mouse
Immunogen
131-230/233
Target
FRAT2
Clonality
Polyclonal
Isotype
IgG
Conjugation
FITC
Source
KLH conjugated synthetic peptide derived from human FRAT2
Applications
WB, IF (IHC-P), IF (IHC-F), IF (ICC)
Purification
Purified by Protein A.
Excitation Emission
494nm/518nm
Concentration
1µg/µl
Dilution
WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
23401
Predicted Cross Reactivity
Human, Rat, Dog, Cow, Sheep
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
